What oral tablets are recommended for the treatment of Myelodysplastic Syndromes (MDS)?

Oral Tablets for Treatment of MDS

Primary Oral Agents

Lenalidomide is the primary oral tablet for MDS, specifically indicated for lower-risk disease with del(5q) cytogenetic abnormality, achieving 60-65% transfusion independence with a median duration of 2-2.5 years. 1

Lenalidomide for Del(5q) MDS

• Lenalidomide 10 mg daily for 21 days every 28 days is the recommended starting dose for transfusion-dependent anemia in lower-risk MDS (IPSS low or intermediate-1) with del(5q), used after erythropoietin-stimulating agent (ESA) failure or ineligibility. 1, 2

• Cytogenetic response occurs in 50-75% of patients, including 30-45% complete cytogenetic responses, which correlates with extended survival and delayed AML progression. 1, 3

• Critical caveat: TP53 mutations, present in ~20% of del(5q) MDS patients, confer resistance to lenalidomide and higher AML progression risk, requiring intensified surveillance and consideration of alternative therapies. 1, 3

• Grade 3-4 neutropenia and thrombocytopenia occur in ~60% of patients during the first weeks, necessitating close blood count monitoring with dose reduction and/or G-CSF support as needed. 1, 3

Lenalidomide for Non-Del(5q) MDS

• For lower-risk MDS without del(5q), lenalidomide can be considered off-label, achieving 26% transfusion independence and 43% overall hematologic improvement, though response rates are lower than in del(5q) patients. 4

• This indication is not approved in the European Union and should be used cautiously, typically after ESA failure. 1, 3

Luspatercept (Oral Consideration)

Luspatercept is approved for very low-, low-, or intermediate-risk MDS with ring sideroblasts (≥15%) or SF3B1 mutation, but it is administered subcutaneously, not orally, achieving 38% transfusion independence ≥8 weeks. 1, 5

• This agent is second-line therapy only, used after documented ESA failure or ineligibility in patients with ring sideroblasts or SF3B1 mutation. 5

• The favorable safety profile includes primarily fatigue, asthenia, dizziness, and diarrhea in the first 4 cycles. 5

Treatment Algorithm for Lower-Risk MDS

For Del(5q) Patients:

1. First-line: ESAs (if serum EPO <500 U/L) 1
2. Second-line: Lenalidomide 10 mg daily for 21/28 days 1, 2
3. Monitor for: TP53 mutations (test at baseline and if resistance develops) 1, 3
4. If lenalidomide fails: Consider azacitidine (if approved), immunosuppressive therapy, or clinical trial 1, 2

For Non-Del(5q) Patients:

1. First-line: ESAs ± G-CSF (if serum EPO <500 U/L) 1
2. Second-line options:
   • Luspatercept (if ring sideroblasts ≥15% or SF3B1 mutation) 1, 5
   • Lenalidomide (off-label, lower response rates) 4
   • Immunosuppressive therapy with ATG ± cyclosporine (if hypocellular marrow, age ≤60, HLA-DR15 positive) 1, 2
   • Azacitidine (if approved for lower-risk) 1, 2

Higher-Risk MDS Considerations

For higher-risk MDS (IPSS intermediate-2 or high, IPSS-R intermediate, high, or very high), oral hypomethylating agents are not standard; azacitidine or decitabine (parenteral) are first-line, preferably as bridge to allogeneic hematopoietic cell transplantation. 2, 6

• Oral decitabine/cedazuridine combination exists but is administered as hypomethylating therapy, not in the same category as lenalidomide. 6

Critical Pitfalls to Avoid

• Never use lenalidomide as first-line therapy before attempting ESAs in appropriate candidates (serum EPO <500 U/L). 1, 5

• Always test for TP53 mutations in del(5q) patients before starting lenalidomide, as these patients have poor outcomes and may benefit from alternative approaches including allogeneic transplant. 1, 3

• Do not continue lenalidomide indefinitely without response; assess response by 4 months and consider alternative therapies if no improvement. 2

• Distinguish MDS from aplastic anemia, as immunosuppressive therapy indications differ significantly between these entities. 7, 8